UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study

PloS one, 2018-10, Vol.13 (10), p.e0204896-e0204896

2018

Volltextzugriff (PDF)

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

Supportive care in cancer, 2015-04, Vol.23 (4), p.1137-1143

2015

Volltextzugriff (PDF)

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients

Clinical and experimental nephrology, 2019-02, Vol.23 (2), p.258-267

2019

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study

Clinical drug investigation, 2018-10, Vol.38 (10), p.945-954

2018

Volltextzugriff (PDF)

A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma

British journal of haematology, 2016-08, Vol.174 (4), p.563-570

2016

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis

Scientific reports, 2019-04, Vol.9 (1), p.6410-11, Article 6410

2019

Volltextzugriff (PDF)

Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial

Supportive care in cancer, 2015-10, Vol.23 (10), p.2891-2898

2015

Volltextzugriff (PDF)

High Hemoglobin Levels Maintained by an Erythropoiesis-Stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment

Therapeutic apheresis and dialysis, 2015-10, Vol.19 (5), p.457-465

2015

Volltextzugriff (PDF)

Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan

Clinical pharmacology: advances and applications, 2018-01, Vol.10, p.101-111

2018

Volltextzugriff (PDF)

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients

Clinical and experimental nephrology, 2019-06, Vol.23 (6), p.739-748

2019

Volltextzugriff (PDF)

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Kidney international, 2018-10, Vol.94 (4), p.818-825

2018

Volltextzugriff (PDF)

Nrf2 activator for the treatment of kidney diseases

Toxicology and applied pharmacology, 2018-12, Vol.360, p.30-37

2018

Volltextzugriff (PDF)

Assessment of CYP‐Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans

Clinical and translational science, 2019-01, Vol.12 (1), p.20-27

2019

Volltextzugriff (PDF)

An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome

Journal of intensive care, 2018-11, Vol.6 (1), p.75-75, Article 75

2018

Volltextzugriff (PDF)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes

International journal of hematology, 2015-10, Vol.102 (4), p.401-412

2015

Volltextzugriff (PDF)

Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate

Kidney international, 2016-11, Vol.90 (5), p.1109-1114

2016

Volltextzugriff (PDF)

Development of intranasal Sendai virus vector-based vaccine against COVID-19

Translational and regulatory sciences, 2021, Vol.3 (3), p.122-124, Article 2021-024

2021

Volltextzugriff (PDF)

Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension

Expert opinion on pharmacotherapy, 2017-12, Vol.18 (18), p.1903-1919

2017

Volltextzugriff (PDF)

Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism

Journal of bone and mineral metabolism, 2017-11, Vol.35 (6), p.616-622

2017

Volltextzugriff (PDF)

Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”

Clinical drug investigation, 2019-01, Vol.39 (1), p.109-111

2019

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First.in.Human Phase I Study

Clinical drug investigation, 2018-10, Vol.38 (10), p.945-954

2018

Volltextzugriff (PDF)

Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses

Cell reports. Medicine, 2022-02, Vol.3 (2), p.100520-100520, Article 100520

2022

Volltextzugriff (PDF)

Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study/Response to Comments on "Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study"

Clinical drug investigation, 2019-01, Vol.39 (1), p.105-111

2019

Volltextzugriff (PDF)

A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Blood, 2014-12, Vol.124 (21), p.4642-4642

2014

Volltextzugriff (PDF)

Correction to: Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients

Clinical and experimental nephrology, 2019-09, Vol.23 (9), p.1173-1173

2019

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(38)
Berichte
(1)

Sprache

Englisch
(37)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients

Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study

A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis

Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial

High Hemoglobin Levels Maintained by an Erythropoiesis-Stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment

Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Nrf2 activator for the treatment of kidney diseases

Assessment of CYP‐Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans

An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes

Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate

Development of intranasal Sendai virus vector-based vaccine against COVID-19

Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension

Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism

Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”

Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First.in.Human Phase I Study

Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses

A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Correction to: Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients

Suchergebnisse filtern